Prioritizing Treatment Goals of People Diagnosed with Bipolar I Disorder in the US: Best-Worst Scaling Results.

"Disclosure John F. P. Bridges has previously served as a consultant for Otsuka and Lundbeck. Joseph F. Goldberg has served as a consultant for BioXcel, Jazz Pharmaceuticals, Lundbeck, Neumora, Neurelis, Otsuka, Sage Pharmaceuticals, Sunovion, Supernus, and Takeda. He is on the Speakers’ bureau for AbbVie, Alkermes, Axsome, Intra-Cellular Therapies, and Sunovion. He has received royalties from American Psychiatric Publishing and Cambridge University Press. At the time of the survey, Heather M. Fitzgerald was a full-time employee of Lundbeck LLC, Deerfield, IL, USA. Sanjeda R. Chumki is a full-time employee of Otsuka Pharmaceutical Development & Commercialization Inc, Princeton, NJ, USA. Kathleen Beusterien and Oliver Will are employees of Cerner Enviza, which provides consulting services to Lundbeck and Otsuka. Leslie Citrome has served as consultant to AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, Impel, INmune Bio, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neurelis, Neurocrine, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, Vanda, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research. He has served as speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and universities and professional organizations/societies. He holds a small number of shares of common stock with Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Pfizer (purchased >10 years ago) and currently has options for acquiring stocks with Reviva. He has received royalties or income from publishing from Taylor & Francis (Current Medical Research and Opinion, 2022–date), Wiley (International Journal of Clinical Practice, through end 2019), UpToDate, Springer Healthcare, Elsevier (Psychiatry, Clinical Therapeutics). The authors report no other conflicts of interest in this work."

"This work was supported by Otsuka Pharmaceutical Development & Commercialization Inc. (Princeton, NJ, USA) and Lundbeck LLC (Deerfield, IL, USA). The sponsors were involved in the design of the study, the collection, analysis and interpretation of data, the writing and reviewing of this article, and the decision to submit the article for publication."

"The study comprised a qualitative (survey development) and a quantitative phase (survey implementation). All research was conducted according to best practice guidelines for Conjoint Analyses published by the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), in accordance with ethical principles specified in the Declaration of Helsinki, International Conference on Harmonization Good Clinical Practices, Good Pharmacoepidemiology Practice, and the applicable legislation on Non-Interventional Studies, and all patients provided informed consent. The study protocol received exemption status from Pearl Institutional Review Board (03 August 2021; board registration number 00007772)."